- Home
- ADPT
as of 01-23-2026 3:41pm EST
$18.46
$0.61
-3.17%
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 2.5B | IPO Year: | 2019 |
| Target Price: | $16.60 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.25 - $20.76 | Next Earning Date: | 02-05-2026 |
| Revenue: | $252,754,000 | Revenue Growth: | 42.57% |
| Revenue Growth (this year): | 50.86% | Revenue Growth (next year): | 0.53% |
AI-Powered ADPT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 0.00%
0.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Adaptive Biotechnologies Corporation (ADPT)
PISKEL KYLE
Sell
Chief Financial Officer
ADPT Jan 12, 2026
Avg Cost/Share
$18.00
Shares
4,290
Total Value
$77,220.00
Owned After
216,637
SEC Form 4
LO FRANCIS
Sell
Chief People Officer
ADPT Jan 12, 2026
Avg Cost/Share
$17.73
Shares
79,590
Total Value
$1,411,130.70
Owned After
315,978
SEC Form 4
ROBINS HARLAN S
Sell
Chief Scientific Officer
ADPT Jan 6, 2026
Avg Cost/Share
$16.44
Shares
10,000
Total Value
$164,400.00
Owned After
1,222,312
SEC Form 4
ROBINS CHAD M
Sell
CEO and Chairman
ADPT Jan 5, 2026
Avg Cost/Share
$15.59
Shares
124,998
Total Value
$1,948,718.82
Owned After
2,584,243
SEC Form 4
LO FRANCIS
Sell
Chief People Officer
ADPT Jan 2, 2026
Avg Cost/Share
$16.08
Shares
3,125
Total Value
$50,250.00
Owned After
315,978
SEC Form 4
LO FRANCIS
Sell
Chief People Officer
ADPT Dec 22, 2025
Avg Cost/Share
$17.50
Shares
4,394
Total Value
$76,895.00
Owned After
315,978
SEC Form 4
LO FRANCIS
Sell
Chief People Officer
ADPT Dec 15, 2025
Avg Cost/Share
$15.57
Shares
113,890
Total Value
$1,773,267.30
Owned After
315,978
SEC Form 4
ROBINS CHAD M
Sell
CEO and Chairman
ADPT Dec 1, 2025
Avg Cost/Share
$18.94
Shares
124,998
Total Value
$2,367,462.12
Owned After
2,584,243
SEC Form 4
PISKEL KYLE
Sell
Chief Financial Officer
ADPT Nov 28, 2025
Avg Cost/Share
$19.50
Shares
162,820
Total Value
$3,174,990.00
Owned After
216,637
SEC Form 4
ROBINS CHAD M
Sell
CEO and Chairman
ADPT Nov 26, 2025
Avg Cost/Share
$19.68
Shares
35,736
Total Value
$703,284.48
Owned After
2,584,243
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| PISKEL KYLE | ADPT | Chief Financial Officer | Jan 12, 2026 | Sell | $18.00 | 4,290 | $77,220.00 | 216,637 | |
| LO FRANCIS | ADPT | Chief People Officer | Jan 12, 2026 | Sell | $17.73 | 79,590 | $1,411,130.70 | 315,978 | |
| ROBINS HARLAN S | ADPT | Chief Scientific Officer | Jan 6, 2026 | Sell | $16.44 | 10,000 | $164,400.00 | 1,222,312 | |
| ROBINS CHAD M | ADPT | CEO and Chairman | Jan 5, 2026 | Sell | $15.59 | 124,998 | $1,948,718.82 | 2,584,243 | |
| LO FRANCIS | ADPT | Chief People Officer | Jan 2, 2026 | Sell | $16.08 | 3,125 | $50,250.00 | 315,978 | |
| LO FRANCIS | ADPT | Chief People Officer | Dec 22, 2025 | Sell | $17.50 | 4,394 | $76,895.00 | 315,978 | |
| LO FRANCIS | ADPT | Chief People Officer | Dec 15, 2025 | Sell | $15.57 | 113,890 | $1,773,267.30 | 315,978 | |
| ROBINS CHAD M | ADPT | CEO and Chairman | Dec 1, 2025 | Sell | $18.94 | 124,998 | $2,367,462.12 | 2,584,243 | |
| PISKEL KYLE | ADPT | Chief Financial Officer | Nov 28, 2025 | Sell | $19.50 | 162,820 | $3,174,990.00 | 216,637 | |
| ROBINS CHAD M | ADPT | CEO and Chairman | Nov 26, 2025 | Sell | $19.68 | 35,736 | $703,284.48 | 2,584,243 |
Latest Adaptive Biotechnologies Corporation News
ADPT Breaking Stock News: Dive into ADPT Ticker-Specific Updates for Smart Investing
Compare ADPT vs Leading Stocks
See how ADPT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ADPT Adaptive Biotechnologies Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.